Kenneth Rosenthal, MD
Ophthalmology · Great Neck, NYNPI 1295750230
Payments from drug & device makers
Across 202 payments — averaging $86.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$6K
- Carl Zeiss Meditec Digital Innovations LLC$3K
- Alcon$818
- Glaukos Corporation$794
- Johnson & Johnson Surgical Vision, Inc.$762
- AbbVie$723
- plus $5K from 28 others
Across 4 payments — averaging $8333.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$33K
- Ophtec USA, Inc.$800
What the payments were for
- Speaking & faculty fees$3,50020%
- Travel & lodging$1,5209%
- Food & beverage$9,65955%
- Entertainment$140%
- Other$2,73816%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 38 | $6,327 |
| Carl Zeiss Meditec Digital Innovations LLC | 1 | $2,738 |
| Alcon | 21 | $818 |
| Glaukos Corporation | 5 | $794 |
| Johnson & Johnson Surgical Vision, Inc. | 14 | $762 |
| AbbVie(2 entities) | 19 | $723 |
| Novartis | 17 | $536 |
| Oyster Point Pharma, Inc. | 26 | $534 |
| Bausch & Lomb Americas Inc. | 8 | $520 |
| Sight Sciences, Inc. | 5 | $473 |
| Ophtec USA, Inc. | 1 | $393 |
| NEW World Medical,inc. | 3 | $309 |
| Tarsus Pharmaceuticals, Inc. | 3 | $270 |
| Rxsight Inc | 4 | $250 |
| Eyepoint US, Inc. | 2 | $232 |
| Kala Pharmaceuticals, Inc. | 5 | $210 |
| Harrow Eye, LLC | 3 | $207 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $192 |
| Dompe US, Inc. | 4 | $186 |
| Ivantis, Inc | 3 | $142 |
| Genentech USA, Inc. | 1 | $125 |
| Bausch Health US, LLC | 1 | $102 |
| Eyevance Pharmaceuticals LLC | 3 | $97 |
| Ocular Therapeutix, Inc. | 1 | $96 |
| Carl Zeiss Meditec, Inc. | 1 | $86 |
| Carl Zeiss Meditec USA, Inc. | 1 | $60 |
| Johnson & Johnson Vision Care, Inc. | 2 | $53 |
| Aerie Pharmaceuticals, Inc. | 2 | $47 |
| Amgen(2 entities) | 2 | $38 |
| Iridex Corporation | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $23 |
| Thea Pharma Inc. | 1 | $22 |
| Optos, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BROMSITE$5,145
- VERACITY SURGICAL$2,738
- CEQUA$628
- XIIDRA$479
- MIEBO$394
- iDoseTR$365
- Tecnis IOL$334
- iDose$334
- VUITY$295
- Ahmed Glaucoma Valve$268
- Kahook Dual Blade$268
- OMNI(R) SURGICAL SYSTEM (US)$261
- Tecnis Simplicity$238
- DEXYCU$232
- Centurion$150
- INVELTYS$144
- EYSUVIS$144
- ACTIVEFOCUS$127
- AcrySof$127
- XELPROS$125
How this compares
$17,431 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 63 | $79,121 |
| XiidraLifitegrast | 15 | $26,259 |
| CequaCyclosporine | 33 | $23,555 |
| LumiganBimatoprost | 49 | $21,023 |
| TyrvayaVarenicline Tartrate | 29 | $19,307 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $18,357 |
| VyzultaLatanoprostene Bunod | 22 | $9,149 |
| MieboPerfluorohexyloctane/Pf | 12 | $8,812 |
| Alphagan PBrimonidine Tartrate | 25 | $6,587 |
| BromsiteBromfenac Sodium | 26 | $6,504 |
| CombiganBrimonidine Tartrate/Timolol | 27 | $5,184 |
| Brimonidine Tartrate | 80 | $4,393 |
| Timolol Maleate | 48 | $2,401 |
| Bromfenac Sodium | 11 | $1,809 |
| Latanoprost | 126 | $903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $723 | $111,915164 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $520 | $44,22149 claims |
| Sun Pharmaceutical Industries Inc.Cequa, Bromsite | $6,327 | $30,05959 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $534 | $19,30729 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $47 | $18,35722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Great Neck
- Philip FerroneGreat Neck$5.8M
- Jonathan JonischGreat Neck$1M
- Kenneth GrahamGreat Neck$959K
- David RheeGreat Neck$699K
- Brett RosenblattGreat Neck$676K
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.